Works matching IS 15330028 AND DT 2017 AND VI 16 AND IP 2
Results: 20
Reviewing the Management of Obstructive Left Colon Cancer: Assessing the Feasibility of the One-stage Resection and Anastomosis After Intraoperative Colonic Irrigation.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Survival Impact of Adjuvant Chemotherapy for Resected Locally Advanced Rectal Adenocarcinoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Prophylactic Use of Oral Dexamethasone to Alleviate Fatigue During Regorafenib Treatment for Patients With Metastatic Colorectal Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Peritoneal Carcinomatosis in Colorectal Cancers - Management Perspective Needs a Change.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
mFOLFOX6 Plus Panitumumab Versus 5-FU/LV Plus Panitumumab After Six Cycles of Frontline mFOLFOX6 Plus Panitumumab: A Randomized Phase II Study of Patients With Unresectable or Advanced/Recurrent, RAS Wild-type Colorectal Carcinoma (SAPPHIRE)-Study Design and Rationale.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Population-Based Patterns and Factors Associated With Underuse of Palliative Systemic Therapy in Elderly Patients With Metastatic Colon Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Ectopic Gastric and Intestinal Phenotypes, Neuroendocrine Cell Differentiation, and SOX2 Expression Correlated With Early Tumor Progression in Colorectal Laterally Spreading Tumors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
- Published in:
- 2017
- By:
- Publication type:
- journal article
Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Peripheral Neutrophil to Lymphocyte Ratio Improves Prognostication in Colon Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The Identifications and Clinical Implications of Cancer Stem Cells in Colorectal Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Adherence, Dosing, and Managing Toxicities With Trifluridine/Tipiracil (TAS-102).
- Published in:
- 2017
- By:
- Publication type:
- journal article
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
- Published in:
- 2017
- By:
- Publication type:
- journal article